AARP Hearing Center
On a cold Sunday night last November, Anthony Fauci, M.D., sat bundled up on his deck, having a (physically distanced) drink with a friend, when the call came. Albert Bourla, the CEO of Pfizer, was on the other end of the line. “Tony,” Bourla said, “are you sitting down?”
Bourla had the results from the phase 3 trials on an mRNA-based vaccine. He told Fauci it was “amazing.”
“Tony, it’s more than 90 percent effective at reducing the risk of developing severe COVID!” Bourla said. For a scientist like Fauci, it was a deeply emotional, cathartic moment.